1. Aptose Biosciences (NASDAQ:APTO) is a clinical-stage biotechnology company specializing in the development of personalized treatments for life-threatening cancers. Today, analyst Joseph Pantginis of HC Wainwright maintained a Buy recommendation for the stock with a target price of $23. Overall, the agreed-upon 12-month target price of all four of the top analysts who recently gave the stock a Buy suggests a huge upside potential of 385.61%. 2. General Motors (NYSE:GM) - General Motors is an American multinational automobile company. On Friday, RBC Capital...